Is UNII-3JB47N2Q2P Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use UNII-3JB47N2Q2P? Is UNII-3JB47N2Q2P safe for nursing mother and child? Does UNII-3JB47N2Q2P extracts into breast milk? Does UNII-3JB47N2Q2P has any long term or short term side effects on infants? Can UNII-3JB47N2Q2P influence milk supply or can UNII-3JB47N2Q2P decrease milk supply in lactating mothers?

Recombinant humanized IgG4k monoclonal antibody that blocks the human integrin alpha-4 subunit making it difficult for T lymphocytes to pass through the meninges. Its use is approved in the treatment of severe forms of multiple sclerosis (EMA 2017) and in Crohn's disease when resistant to other treatments (Yarur 2013, FDA 2012). Its very high molecular weight explains the small or zero transfer into milk observed (Hainke 2015, Baker 2015). Of three mothers in whom the concentration of UNII-3JB47N2Q2P in breast milk was measured, detectable levels only appeared in two. With these measurements, expert authors have calculated a relative dose for the infant of no concern, around 1.7% or, if the maximum peak is considered, 5.3%. But in addition, its low oral bioavailability would hinder its transfer into the infant's plasma via ingested breast milk because, due to its protein nature, it degrades in the gastrointestinal tract, and is not absorbed (Cree 2013), except in premature infants and the immediate neonatal period where there may be greater intestinal permeability. Despite the low excretion in breast milk and the lack of intestinal absorption by the infant, due to the long elimination half-life and the limitation of the number of available reports, opinions among experts are divided between those who do not recommend it (Mahadevan 2017), those who think that it is probably compatible (Almas 2016, Baker 2015, Briggs 2015) and those who have not expressed an opinion due to lack of sufficient studies (Hainke 2015, Damas 2015, Cree 2013, Houtchens 2013, Yarur 2013, Mahadevan 2011) , with experts being more in favor of discouraging it in Europe than in the USA (Alroughani 2016). Other monoclonal antibodies similar to UNII-3JB47N2Q2P, such as adalimumab, infliximab and certolizumab, are considered low risk and probably compatible with breastfeeding (Damas 2015, van der Woude 2010). See below the information of these related products:

UNII-3JB47N2Q2P is excreted into breastmilk in some, but not all, women. The time of the peak level in breastmilk is variable, but might be as long as 6 months. Because UNII-3JB47N2Q2P is a large protein molecule with a molecular weight of about 149,000, absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Some experts recommend avoiding breastfeeding with UNII-3JB47N2Q2P, while others do not.[1][2][3] Until more data become available, UNII-3JB47N2Q2P should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

In a multi-center study of women with inflammatory bowel disease in pregnancy (the PIANO registry), 8 women received UNII-3JB47N2Q2P while breastfeeding their infants. Among those who received UNII-3JB47N2Q2P or another biologic agent while breastfeeding, infant growth, development or infection rate was no different from infants whose mothers received no treatment. An additional 68 women received a biologic agent plus a thiopurine. Infant outcomes were similar in this group.[3]